Tocqueville Asset Management L.P. Akebia Therapeutics, Inc. Transaction History

Tocqueville Asset Management L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 31, 2019	SELL	$4.1 - $8.05 $87,329 - $171,465	-21,300 Closed	0 $0
Q1 2019 Apr 30, 2019	SELL	$5.41 - $8.73 $27,050 - $43,650	-5,000 Reduced 19.01%	21,300 $174,000
Q4 2018 Feb 08, 2019	SELL	$5.39 - $9.15 $61,984 - $105,225	-11,500 Reduced 30.42%	26,300 $145,000
Q3 2018 Nov 13, 2018	BUY	$7.44 - $10.65 $281,232 - $402,570	37,800 New	37,800 $334,000

120

54.9M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $438M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Tocqueville Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on Tocqueville Asset Management L.P. with notifications on news.